Dr. Reddy's API plant still struggling to satisfy FDA

Dr. Reddy's tablets
Dr. Reddy's Laboratories has received another Form 483 for a plant that makes APIs used to manufacture finished products. (Dr. Reddy's)

Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing raises issues about out-of-spec drugs and cleaning of solvents off equipment at the plant.  

The highly redacted, five-observation Form 483 is for Dr. Reddy’s Unit VI API plant in Srikakulam District, Andhra Pradesh, one of three plants cited in a 2015 warning letter. Among other issues, the January inspection was critical of the plant’s investigations of out-of-specification tests. It also said the plant did not even test “for unknown peaks in residual solvents,” in one batch of drugs.

RELATED: Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

The inspectors' observations about the plant's equipment cleaning focused in part on production of an API that the citation does not publicly name. It said an unsatisfactory cleaning validation might be associated with OSS peaks in it and "unknown peaks in other manufactured APIs … which are pending applications in the United States.” It also faulted the company for not conducting a trend analysis on those peaks. 

RELATED: What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint

The inspection report does not name any specific drugs but the discussion of solvents, mentioned six times, underscores the FDA’s focus on them after finding that solvents play a key part in the creation of suspected carcinogens in sartans and ranitidine drugs. 

Dr. Reddy’s is among drugmakers that voluntarily recalled ranitidine, generic Zantac, from the market last year after the FDA determined that unacceptable levels of N-nitrosodimethylamine were being created through manufacturing. The company reported the recall of 33 different ranitidine products last fall cost it about $25 million in that quarter. 

Read more on

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.